Literature DB >> 24588467

Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Amanda Gwee1, Noel Cranswick.   

Abstract

There are a number of challenges to using anti-infective agents in children and pregnant women. There is limited understanding of the altered pharmacokinetics of anti-infectives in these populations and as a result, optimized dosing regimens are yet to be established. The potential adverse effects of the drug on pregnancy outcome and the developing foetus is a major consideration, and the long term implications of drug side effects must be taken into account when drug exposure occurs early in life. These factors hinder research and licensing of new anti-infective drugs in these populations. We describe the current deficiencies and future challenges of anti-infective use in children and pregnant women, providing specific examples.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  antibacterial; antifungal; antimicrobial; child; infant; pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 24588467      PMCID: PMC4309628          DOI: 10.1111/bcp.12363

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  46 in total

1.  Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient.

Authors:  K A Aleck; D L Bartley
Journal:  Am J Med Genet       Date:  1997-10-31

2.  A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.

Authors:  G Lefèvre; S Looareesuwan; S Treeprasertsuk; S Krudsood; U Silachamroon; I Gathmann; R Mull; R Bakshi
Journal:  Am J Trop Med Hyg       Date:  2001 May-Jun       Impact factor: 2.345

3.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

Review 4.  Malaria in pregnancy.

Authors:  Christopher J M Whitty; Sally Edmonds; Theonest K Mutabingwa
Journal:  BJOG       Date:  2005-09       Impact factor: 6.531

5.  Fluconazole-induced congenital anomalies in three infants.

Authors:  T J Pursley; I K Blomquist; J Abraham; H F Andersen; J A Bartley
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

Review 6.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.

Authors:  Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

8.  Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.

Authors:  C R Rayner; C C Bulik; M A Kamal; D K Reynolds; S Toovey; J P Hammel; P F Smith; S M Bhavnani; S A Van Wart; P G Ambrose; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

Review 9.  Systemic colistin use in children without cystic fibrosis: a systematic review of the literature.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; Petros I Rafailidis
Journal:  Int J Antimicrob Agents       Date:  2009-01-24       Impact factor: 5.283

10.  Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.

Authors:  Thereza Piloya; Sabrina Bakeera-Kitaka; Adeodata Kekitiinwa; Moses R Kamya
Journal:  J Int AIDS Soc       Date:  2012-07-02       Impact factor: 5.396

View more
  1 in total

1.  From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.

Authors:  Jennifer H Martin; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.